Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 12/02/2019
Change 5-day change 1-year change 3-year change Capi.($)
+0.17%+4.35%+72.39%+114.97% 73.45B
+0.78%+15.22%+56.85%+92.24% 62.99B
-0.23%-2.90%+0.97%+483.86% 28.05B
-1.40%+4.81%+60.85%+20.35% 25.42B
+23.10%+23.42%+2.75%-2.61% 23.3B
+2.47%+5.69%+42.07%-13.71% 19.45B
-0.71%-4.11%+243.99%+423.83% 18.16B
-3.50%-0.95%+14.80%+515.88% 16.53B
+2.48%+7.74%+44.67%+154.00% 13.16B
Average +2.58%+3.23%+59.93%+198.76% 31.17B
Weighted average by Cap. +2.03%+5.48%+59.24%+164.95%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-